A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer. - A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.

Toho University Omori Medical Center0 个研究点目标入组 35 人开始时间: 2011年7月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan. 2)Patients with active co-morbidities including severe conditions. 1.uncontrollable angina pectoris, myocardial infarction within 3 months, severe heart disease. 2.uncontrollable diabetes, hypertension. 3.severe infection 4.paresis of intestine, illeus 5.Hemoptysis(more than 2.5ml), continuous or treatment-required bloody sputum 6.Great vessel involvement 7.Melena 8.Receiving anticoagulant drug 9.Uncontrolled urinari protein 10.CongenitalbleedingdiathesisCoagulation abnormalities 11.Patients whose participation in the trial is judged to be inappropriate by the attending doctor. 3)Patients with massive pleural and cardiac effusion and ascites that need to be immediately treated. 4) Brain metastases with neurological symptoms. 5) Active double cancer. 6)Pregnancy, breast feeding and suspected pregnancy. 7)History of grave drug allergic reaction. 8) Psychiatric disorder. 9) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor.

发起方